% | $
Quotes you view appear here for quick access.

Taxus Cardium Pharmaceuticals Group, Inc. Message Board

  • globalthehappytrader globalthehappytrader Apr 11, 2013 12:46 PM Flag

    Excellagen and capital efficient Cardium

    Cardium Therapeutics, Inc. (CXM) Commercialization Status for Excellagen
    Cardium Therapeutics has a capital-efficient, asset-based business strategy focused on building a diversified portfolio of new and innovative bio-medical product opportunities and businesses, leveraging research and development investments by big pharma, venture, and institutional investors. A key component to that strategy is the company’s Excellagen advanced wound care management platform, which has already received FDA 510(k) clearance for U.S. marketing and sales.

    Principal commercialization factors:
    • Excellagen is the best-in-class acellular biological modulator designed to accelerate the growth of granulation tissue for wound healing.
    • Excellagen has FDA clearance for the treatment of a broad array of dermal wounds.
    • Excellagen is competitively positioned, offering an aseptically manufactured, pharmaceutically-formulated collagen in a flowable syringe-based format that is easy to use. !!!!! Is it??!!!!
    • Excellagen has multiple clinical studies backing up its unique effectiveness.
    • Selected as 2012 Top 10 Innovation in Podiatry by Podiatry Today magazine.
    • Excellagen outsourced supply chain is fully operational, including U.S. cold chain distributor: S Is it

    So where are the salesnumbers???

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.1680.000(0.00%)Aug 25 1:00 PMEDT